Bladder Function Disorders Common in Refractory Nocturnal Enuresis
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 4, 2023 -- Children with refractory monosymptomatic (MNE) and nonmonosymptomatic (NMNE) primary nocturnal enuresis have considerable prevalence of bladder function disorders, according to a study published in the October issue of Health Science Reports.
Farzaneh Sharifiaghdas, from the Shahid Beheshti University of Medical Sciences in Tehran, Iran, and colleagues enrolled 96 neurologically normal children aged 5 to 18 years (44 boys and 51 girls), 41 and 55 (38.8 and 61.2 percent) of whom had refractory MNE and refractory NMNE, respectively. Urodynamics of all children were assessed to detect any underlying bladder overactivity.
The researchers identified detrusor overactivity (DO), low bladder capacity, low compliance, and increased postvoid residual (PVR) in 70, 35, 43, and 76 patients, respectively. Mean bladder compliance was 21.66 ± 14.52 mL/cmH2O. Overall, 90.9 and 97.5 percent of the NMNE and MNE patients, respectively, had abnormal urodynamic findings. A significant relationship was seen between NMNE and increased PVR and abnormal voiding patterns. Significant associations were seen for both high PVR and DO with obstructive urinary symptoms. No significant association was observed for constipation and history of urinary tract infection with urodynamic study abnormality.
"These urodynamic findings offer valuable insights for guiding the assessment and tailored treatment of children grappling with primary refractory nocturnal enuresis," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.